Abstract
Results of a phase II study combining, weekly irinotecan with pharmacokinetics (PK) adaptation of 5FU “Gamelin” schedule in first line in patients with metastatic colorectal cancer (MCRC)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
